Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103

BIOLOGICAL2 trials

Sponsors

Tcelltech Inc.

Conditions

High-grade GliomaSolid TumorsWHO Grade Ⅳ Glioma

Phase 1

Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.

RecruitingNCT06482905

Tcelltech Inc.High-grade Glioma, WHO Grade Ⅳ Glioma

Start: 2024-09-04End: 2027-06-01Target: 52Updated: 2026-03-24

Phase I Study of TX103 CAR-T Cells in Participants With Advanced Solid Tumors

RecruitingNCT07231081

Tcelltech Inc.Solid Tumors

Start: 2025-10-16End: 2027-12-20Target: 85Updated: 2025-11-17